Medpace Holdings, Inc. (MEDP) Business Profile

What it does

Medpace is a clinical contract research organization, or CRO. It sells outsourced clinical development services to biotechnology, pharmaceutical and medical device companies. Its customers hire it to help design and conduct studies that test potential treatments in people, as well as to prepare information for regulators.

The company offers services across Phase I through Phase IV clinical trials. Its medical specialists help plan studies, train operational staff, monitor medical issues and work with investigators and regulators. Clinical trial managers oversee execution, while other teams select countries and sites, help recruit and retain patients, and monitor research sites.

Medpace also provides regulatory guidance, medical writing, statistical analysis, clinical data management and drug-safety reporting. Its laboratories offer services such as testing trial samples, managing specimens, analyzing imaging and cardiovascular data, and developing tests for biological samples. Its clinics conduct studies involving healthy volunteers and patient populations.

The company works across a range of therapeutic areas, including oncology, metabolic disease, cardiology, central nervous system disorders, and antiviral and anti-infective treatments. Its full-service model brings medical, operational, laboratory and regulatory work together under customer contracts. Medpace uses ClinTrak, its proprietary clinical-trial information management system, to give trial managers access to study metrics.

How it makes money

Medpace earns fees for performing services specified in customer contracts. It reports one segment, with FY2025 revenue of $2.5 billion. A latest-quarter total is not provided here.

Contracts are typically priced using either a fixed fee or a unit-of-service model. Each is negotiated around the expected scope, complexity and performance risks of the project. Pricing also considers third-party activities and other costs needed to deliver the work that customers reimburse. Contracts can last from a few months to several years.

Most contracts provide for an upfront payment at signing. Medpace collects the balance during the contract, either on an agreed billing schedule or when it completes specified targets or milestones. Billing and cash collection are separate from revenue recognition: the company generally recognizes revenue over time as it performs the services, primarily measuring progress using a cost-to-cost method.

Customers can cancel contracts immediately or with advance notice specified in the contract, typically 30 days. On cancellation, Medpace is entitled to fees for services performed and reimbursable costs incurred, including necessary study closeout work. Those fees are generally agreed with the customer and recognized when they can be reliably estimated and collection is probable.

Oncology accounted for 29.5% of FY2025 revenue, while metabolic work accounted for 16.1%. Revenue also comes from other therapeutic areas and services. Period-to-period revenue depends on new business, work performed on active studies, cancellations, changes in estimated costs and the mix and stage of studies.

Customers and how it sells

Medpace serves small and mid-sized biopharmaceutical companies as well as large pharmaceutical companies. It also markets its services to medical device companies. Its approach focuses on customers seeking full-service outsourcing and matches potential clients with the company’s therapeutic expertise.

An integrated sales and marketing team seeks work from both new and existing customers. Medical and scientific experts join discussions early, helping develop a study design, regulatory plan and execution plan that the sales team can carry into a proposal. Marketing supports the process through campaigns, conferences and research to identify potential customers.

Medpace had approximately 6,200 employees across 46 countries as of December 31, 2025. Its central laboratories operate in Cincinnati, Ohio; Leuven, Belgium; Shanghai, China; and Singapore. Its bioanalytical laboratory and clinics are on its Cincinnati clinical research campus. Trial teams also consider countries and research sites when planning studies, and work under the regulations applicable in each jurisdiction.

The company may take payment risk through arrangements such as strategic investments, flexible payment terms, fee financing or trial-execution risk sharing with customers or other drug companies.

Suppliers and costs

Medpace’s direct costs are driven primarily by employee labor and benefits. They also include third-party service expenses, fees paid to research-site investigators, reimbursed out-of-pocket expenses and laboratory supplies. Office rent, utilities, supplies and software licenses are allocated between service delivery and administrative functions according to their estimated use.

The company sometimes hires subcontractors, including laboratories or medical diagnostic specialists, to conduct parts of a trial. It is responsible for their performance and may be liable if they fail to meet their contract terms. Medpace also operates its own laboratories and clinics.

Selling, general and administrative expenses include compensation and benefits, facilities and software costs, professional fees, travel and marketing. Direct costs are expensed as incurred, rather than deferred while the company awaits contract awards or changes in scope. Their proportion of revenue can vary with workforce changes, compensation, labor efficiency and the mix of services.

For the year ended December 31, 2025, total direct costs were $1,769.6 million. The increase from the prior year primarily reflected higher reimbursed out-of-pocket expenses and personnel costs supporting increased service activity.

Competitive position

Medpace competes for clinical development work against other full-service CROs and against research and development departments inside biopharmaceutical companies. Its named major CRO competitors include IQVIA Holdings, ICON, PPD, now part of Thermo Fisher Scientific, and Fortrea. Specialty and regional CROs also compete for work.

Customers can assess providers on therapeutic experience, staff and service quality, reliability, service breadth, price and the ability to recruit investigators and patients. Global reach, the ability to manage large trials and speed of completion are also competitive factors. Medpace says the industry includes several hundred smaller, narrowly focused providers and a small number of full-service companies with global capabilities.

Medpace’s model combines therapeutic specialists, trial operations, laboratories, regulatory services and its ClinTrak system. The company believes that the cost and experience needed to build therapeutic expertise, global infrastructure and regulatory capabilities create barriers to becoming a broad global provider.

Our reading: the breadth of services and established international operations offer a meaningful competitive foundation, since a provider needs people and infrastructure across several functions to run global trials. Our reading: therapeutic expertise and ClinTrak support execution, but the evidence does not establish that either prevents customers from moving work to another CRO or handling it internally.

Growth opportunities

Medpace’s strategy is to expand its share of the Phase I–IV CRO market by conducting trials across therapeutic areas. Its sales team seeks both new customers and additional work from existing ones, with medical and scientific experts involved early in the sales process. The company expects to continue expanding through organic growth and potentially selective bolt-on acquisitions and investments.

For the year ended December 31, 2025, revenue was $2,530.2 million, compared with $2,109.1 million for the year ended December 31, 2024. Medpace attributed the increase primarily to activity in metabolic, oncology and central nervous system work. Oncology revenue was $747.6 million in FY2025, while the revenue category labeled Other was $745.0 million.

Net new business awards were $2,646.8 million for the year ended December 31, 2025, compared with $2,230.0 million for the year ended December 31, 2024. The measure represents new awards less cancellations. Backlog was $3,027.2 million as of December 31, 2025; Medpace expected approximately $1,890.0 million to $1,910.0 million of that amount to convert to net revenue in 2026.

Awards and backlog can change with study scope, cancellations and timing. Medpace says they may not be reliable indicators of future-period revenue.

Structural risks

• Contract loss and customer payment: Customers may delay, cancel or decline to renew work, or fail to pay for services performed. Trials can end because of financing constraints, regulatory actions, disappointing results or insufficient patient enrollment.

• Customer research spending: Changes in biopharmaceutical outsourcing, aggregate expenditures and research and development budgets could affect Medpace’s results and growth. Customers can also shift work to another CRO or their own internal resources.

• Regulatory and trial liability: Failure to follow contracts, regulations or ethical requirements can lead to costs, liability or reputational harm. A poorly conducted trial may have to be repeated at Medpace’s expense, and the company can face injury claims arising from trials.

• Systems and data: The business depends on information systems including ClinTrak. Failures, cyberattacks or breaches could interrupt service delivery and lead to loss or unauthorized disclosure of data.

• International operations and personnel: Different national rules, political and economic conditions, currency movements and geopolitical issues can affect operations or delay trials. The company also depends on recruiting and retaining experienced professional, scientific and technical staff.

• Founder control: The chief executive officer and founder controls a substantial amount of outstanding common stock, and his interests may differ from or conflict with those of other shareholders.

Bottom line

Our reading

Medpace is a service business built around running clinical trials, with revenue earned as work progresses under contracts that can span several years (item1; item7). Its breadth of medical, operational and laboratory capabilities supports its full-service model, while customers’ ability to cancel studies makes backlog an imperfect guide to future revenue (item1; item7). Execution, regulatory compliance, skilled staff and customer research spending remain important to the business (item1; item1a).